bivalent BNT162b2 (original/Omi BA.4/BA.5)

BIOLOGICAL2 trials

Sponsors

BioNTech SE, Pfizer

Conditions

COVID-19Healthy ParticipantsInfluenza, Human

Phase 2

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

CompletedNCT05596734

BioNTech SECOVID-19, Influenza, Human

Start: 2022-10-28End: 2023-12-28Updated: 2025-07-23

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

CompletedNCT05886777

PfizerHealthy Participants

Start: 2023-06-05End: 2024-01-01Updated: 2024-12-18

Related Papers

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Vaccines2025-02-053 citations

571. Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Open Forum Infectious Diseases2025-01-29